Lilly’s Taltz and Zepbound combo shows durable results in year-long study

The TOGETHER-PsO and TOGETHER-PsA trials followed adults living with moderate-to-severe plaque psoriasis or active psoriatic arthritis alongside obesity. By the 52-week mark, participants receiving the dual therapy maintained the superior outcomes observed at Week 36, outperforming those treated with Taltz alone. In the psoriasis study, 30.6% of patients on the combination therapy achieved complete skin clearance and at least 10% weight loss, compared to 4.4% in the monotherapy group. For those with psoriatic arthritis, 39.2% reached a 50% reduction in disease activity and significant weight loss, versus 1.7% for the Taltz-only cohort.

Beyond primary clinical endpoints, the study noted sustained improvements in systemic inflammation and metabolic health, including blood pressure and cholesterol levels. Dr. Mark Genovese, senior vice president of Lilly Immunology development, noted that these findings support a more comprehensive approach to patient care, moving away from disconnected treatments for the skin, joints, and weight. Safety data remained consistent with the known profiles of both medications, with adverse events reported as mild to moderate. These results provide a clearer picture of how managing immunometabolic health can benefit patients who struggle with the cumulative burden of these chronic, overlapping conditions.